Vital NICE nod for Jazz’s Epidyolex
UK-wide therapy for patients who have seizures linked to tuberous sclerosis complex
Read More
Tag: Jazz
Jazz Pharmaceuticals receives SMC approval for reimbursement of Sativex
Therapy is for the treatment of spasticity due to multiple sclerosis
Read More
Jazz and Redx in milestone inhibitor agreement
Jazz Pharmaceuticals and Redx announce that pan-RAF inhibitor will enter clinical development
Read More
Jazz Pharmaceuticals reveals new manufacturing facility for cannabis-based medicines
The site in Kent will support the manufacture of regulatory approved cannabis-based medicines while also leveraging environmental practices
Read More
Jazz’ small cell lung cancer therapy wins US green light
The approval gives patients who relapse a new second-line option for the first time in nearly 20 years
Read More
Positive PhIII data for Jazz sleep disorder drug
JZP-258 achieved primary and key secondary endpoints showing significant differences in weekly number of cataplexy attacks and Epworth Sleepiness Scale scores compared to placebo
Read More
NICE nod for Jazz’ AML chemo
Jazz Pharmaceuticals’ chemotherapy Vyxeos has won the backing of the National Institute for Health and Care Excellence (NICE) for routine use on the NHS in England and Wales to treat certain acute myeloid leukaemias (AML).
Read More
Jazz’ Vyxeos wins EU nod for certain acute myeloid leukaemias
Dublin, Ireland-based Jazz Pharmaceuticals will be celebrating news of European approval of its leukaemia drug Vyxeos.
Read More
Speedy review for Jazz’ high-risk AML chemo
Dublin, Ireland-based Jazz Pharmaceuticals’ Vyxeos is being given a speedy review in Europe as a treatment for certain types of high-risk acute myeloid leukemia (AML).
Read More
